Abstract:OBJECTIVE:To evaluate the safety and validity of neo-adjuvant chemoradiotherapy followed by surgery for locally advanced esophageal carcinoma.METHODS:Patients with IIB, III staged squamous cell carcinoma of thoracic esophagus were randomly allocated to either preoperative chemoradiotherapy followed by surgery (arm A) or surgery alone (arm B). In arm A, chemotherapy and radiotherapy were performed concurrently. Patients received two cycles of vinorelbine and cisplatin. Vinorelbine at 25 mg/m(2) per day was administered as a bolus infusion at d1, d8, d22 and d29. Cisplatin at 75 mg/m(2) was administered by an intravenous infusion at d1 and d22 (or 25 mg/m(2) days 1 - 4 and 22 - 25). A total radiotherapeutic dose of 40 Gy was delivered in 20 daily fractions of 2.0 Gy each (5 d/wk for 4 weeks). Three-incisioned esophagectomy was performed at Weeks 4 - 6 after chemoradiotherapy. Primary outcome was overall survival time. An interim analysis was performed in June 2011.RESULTS:From July 2007 to June 2011, 123 eligible patients were randomly assigned at 7 cooperative cancer centers (54 cases in arm A vs 69 cases in arm B). In arm A, the clinical response rate of chemoradiotherapy was 90.7%. All patients finished the preoperative chemoradiotherapy. Forty-nine cases continued to receive esophagectomy. The pathological complete response rate was 29.6%. The rate of R0 resection in arm A was significant higher than that in arm B(96.0% vs 85.5%, P = 0.015). The most common grade 3/4 toxicity of chemoradiotherapy was leukopenia occurring in 33 cases (61.1%). Vomiting and esophagitis were usually of Grade 1/2. No patient died or abandoned surgery because of chemoradiation toxicity. Between arms A and B, operative duration, blood loss, duration of chest tube drainage and length of postsurgical hospital stay were similar. The incidences of postoperative heart failure (2.0% vs 1.4%, P = 1.000), anastomotic leakage (8.2% vs 11.6%, P = 0.759) and hoarseness (6.1% vs 4.3%, P = 0.691) were not significantly different. The incidence of pulmonary infection in arm A was slightly higher than that in arm B (8.2% vs 1.4%, P = 0.094). No perioperative deaths occurred in either group. There were no significant differences in overall survivals at 1, 2 years between arms A and B (85.6%/75.5% vs 79.1%/66.1%, P = 0.207). The disease-free survivals at 1, 2 years in arm A were slightly higher than in arm B (86.6%/83.2% vs 70.9%/61.8%, P = 0.075).CONCLUSION:Neo-adjuvant chemoradiation followed by surgery may achieve a high clinical response rate and pathologic complete tumor regression rate. It significantly increases the R0 resection rate and down stage the esophageal cancer patients. But its ultimate efficacy awaits further follow-up studies.

Clinical Study of Intensity Modulated Radiotherapy Combined with Chemotherapy in the Treatment of Non-surgical Patients with Locally Advanced Esophageal Carcinoma

Long-Term Treatment Outcomes of the Elder Patients with Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma with Definitive Chemoradiotherapy or Radiotherapy.

Clinical Study of Late-Course Three-Dimensional Conformal Radiotherapy for Esophageal Carcinoma

A Comparative Study between Intensity Modulated Radiation Therapy and Combined Radio-chemotherapy for Treatment of Esophagus Cancer Patients

Postoperative Concurrent Chemoradiotherapy for Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma: A Phase II Clinical Trial

Phase 2 Study of Intensity-Modulated Radiation Therapy and Concurrent Chemotherapy for Inoperable Locally Advanced Esophageal Squamous Cell Carcinoma

A Meta-analysis of survival of middle and late stage esophageal carcinoma treated with radiotherapy combined with traditional Chinese medicine

Effective Treatment of Esophageal Carcinomas Using Intensity-Modulated Radiotherapy in Combination with Nedaplatin and Docetaxel

Evaluation of the safety and effectiveness of neoadjuvant combined chemoimmunotherapy in the treatment of locally advanced esophageal squamous cell carcinoma: a retrospective single-arm cohort study

Different Radiation Treatment in Esophageal Carcinoma: a Clinical Comparative Study.

Clinical Research of Raltitrexed Plus Nedaplatin Combined with Concurrent Radiotherapy for Loco-Regional Recurrence of Esophageal Carcinoma after Surgery

Clinical Study of Concurrent Chemoradiotherapy or Radiotherapy Alone for Esophageal Cancer Patients with Positive Lymph Node Metastasis.

Clinical study of postoperative chemoradiotherapy of thoracic esophageal squamous cell carcinoma with positive lymph nodes

Stereotactic Radiotherapy and Chemotherapy for Esophageal Carcinoma

The Clinical Observation of Low-Dose Paclitaxel Chemotherapy Combined with Concurrent Radiotherapy in the Treatment of Advanced Esophageal Squamous Cell Carcinoma

Concurrent Three Dimensional Conformal Radiotherapy and Chemotherapy with DF Regime in the Treatment for 33 Cases with Advanced Esophageal Carcinoma

[A Multi-Centered Randomized Controlled Study of Neo-Adjuvant Chemoradiotherapy Followed by Surgery Versus Surgery Alone for Locally Advanced Squamous Cell Carcinoma of Esophagus: an Interim Analysis].

Clinical observation of docetaxel combined with cisplatin in treatment of advanced esophageal cancer with synchronous radiotherapy

The Prognosis and Feasibility of Extensive Clinical Target Volume in Postoperative Radiotherapy for Esophageal Squamous Cell Carcinoma: A Phase II Clinical Trial

Concurrent chemoradiotherapy versus radiotherapy alone for patients with locally advanced esophageal squamous cell carcinoma in the era of intensity modulated radiotherapy: a propensity score‐matched analysis

Esophagectomy after Concurrent Chemoradiotherapy Improves Locoregional Control in Clinical Stage II or III Esophageal Cancer Patients